INSUBCONTINENT EXCLUSIVE:
Good morning!
The domestic stock market on Monday showed early signs of a possible breakout from its consolidation range
The brokerage remains positive on Ajanta Pharma given the improving prospects of a revival in its earnings growth
Capex is nearly complete and benefits are likely to accrue from end of FY20, said Motilal Oswal
Infrastructure Developers and revised fair value to Rs 154 from Rs 145
Toll collections for IRB are set to improve on the company bagging the tolling and maintenance of the Mumbai-Pune project for 10 years, said
With GIC payment also coming through, the brokerage expects IRB to benefit from the partnership in the current and upcoming projects
demand scenario.Considering the subdued macro-economic environment, the brokerage expects growth recovery to be gradual and given the
tailwind of copra price is in the base and it does not expect material gross margin expansion in the near future
Automotive and revised fair value to Rs 150 from Rs 170
The brokerage expects demand conditions to remain challenging in both India and Europe in the first half of calendar year 2020
The brokerage has cut its EPS estimates for 2020 and 2021 by 19-20 per cent
The company's top-four brands in the domestic market, Metrogyl price increase and potential market-share gains in Rantac would provide a 5
per cent-point boost to the India business growth and incremental margins of around 200-225 bps in FY21, said IIFL
JB Chemicals also targets scaling-up its CMO business, driven by existing relationships and on-boarding of new clients which will
furtherimprove the business mix, said IIFL
Shares of JB Chemicals ended down 3.5 per cent at Rs 537.40 on Friday.